Graftys Acquires Biologics4Life

Graftys, manufacturer of bone graft substitutes for orthopedic surgery, announces its acquisition of Biologics4Life, developer of a new generation of injectable synthetic bone graft materials. To achieve its new development and commercial ambitions, Graftys raised $3 million from Go Capital via its Ouest Venture 3 fund along with Noshaq and other...

document icon

You are out of free articles for this month

Subscribe as a Guest for $0 and unlock a total of 5 articles per month.

You are out of five articles for this month

Subscribe as an Executive Member for access to unlimited articles, THE ORTHOPAEDIC INDUSTRY ANNUAL REPORT and more.


Julie Vetalice is ORTHOWORLD's Editorial Assistant. She has covered the orthopedic industry for over 20 years, having joined the company in 1999.

Contact Us